InnoCan Pharma logo

InnoCan Pharma(OTC) INNPF

Market Cap$6.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-89%
5 Year-98%
1 Year-89%
1 Month-5%
$1.40
+0.00%
+0.00Today
InnoCan Pharma last closing stock price
MetricPriceDate
Last closeUSD 1.402026-10-01
InnoCan Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-20%USD 1.752026-09-21
1 month-5.41%USD 1.482026-09-01
3 month-12.5%USD 1.602026-07-02
Year to date-80.64%USD 7.232025-12-30
1 year-89.16%USD 12.922025-10-01
3 year-90.36%USD 14.522023-09-26
5 year-97.62%USD 58.842021-10-01
Since inception-88.82%USD 12.532020-11-27

InnoCan Pharma Financials at a Glance

Market Cap

$6.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$23.30M

Net Income (TTM)

-$943.67K

EPS (TTM)

-$0.21

P/E Ratio

-6.58

Dividend

$0.00

Beta (Volatility)

1.68 (High)

Price

$1.40

Volume

164

Open

$1.40

Previous Close

$1.40

Daily Range

$1.40 - $1.40

52-Week Range

$1.40 - $14.26

Estimated Earnings Date

Nov 19, 2025

INNPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InnoCan Pharma

INNOCAN PHARMA Corp is a pharmaceutical company focused on developing innovative drug delivery systems that integrate cannabidiol (CBD) with various pharmaceutical ingredients. The company operates in multiple international markets, including the United States and Europe, and is dedicated to advancing research in CBD applications for various health conditions.

Products and Services
  • CBD-loaded exosomes for treating conditions like COVID-19
  • CBD-infused liposomes for enhanced drug delivery
  • Branded topical treatments, including CBD eye serum and recovery lotion
Growth Outlook
  • Expansion into international markets enhances revenue potential
  • Ongoing R&D in CBD applications positions the company for future growth
  • Increasing consumer demand for CBD products supports market expansion
Financial Highlights
  • Recent quarterly revenue of 5.12 million, showing strong market interest
  • Gross profit margin of approximately 90% indicates effective cost management
  • Cash reserves of 6.44 million provide a solid financial foundation
INNOCAN PHARMA Corp is strategically positioned in the growing CBD market, with a focus on innovative product development and international expansion. The company's commitment to research and development, particularly in CBD applications, is expected to drive future growth. Recent financial performance highlights, including a significant gross profit margin and healthy cash reserves, reflect the company's operational efficiency and potential for sustained success. As consumer interest in CBD products continues to rise, INNOCAN PHARMA Corp is well-placed to capitalize on emerging opportunities in the pharmaceutical sector.
AI Generated • Sep 15, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9

CEO

Iris Or Gabi Bincovich

Website

www.innocanpharma.com

Headquarters

Calgary, AB T2P 0N7, CA

INNPF Financials

Key Financial Metrics (TTM)

Gross Margin

90.45%

Operating Margin

-14.60%

Net Income Margin

-4.02%

Return on Equity

-19.37%

Return on Capital

-19.22%

Return on Assets

-9.11%

Earnings Yield

-15.20%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.50M

Volume

164

Avg. Volume

45.047

Financials (TTM)

Gross Profit

$21.08M

Operating Income

-$3.41M

EBITDA

-$1.08M

Operating Cash Flow

-$1.51M

Capital Expenditure

-$18.73K

Free Cash Flow

-$1.53M

Cash & ST Invst.

$6.44M

Total Debt

$1.66M

InnoCan Pharma Performance Analysis

InnoCan Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,559,0001205.6%
20232023-12-31USD 13,657,000433.7%
20242024-12-31USD 29,437,000115.5%
20252025-12-31USD 26,612,000-9.6%
InnoCan Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-3.7%
Q42025-12-31-24.9%
Q12026-03-3125.9%
Q22026-06-30-19.7%
InnoCan Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.98-66.2%
20232023-12-31USD -1.1921.0%
20242024-12-31USD -0.43-64.2%
20252025-12-31USD -0.25-41.0%
InnoCan Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-230.8%
Q42025-12-31202.3%
Q12026-03-31-147.7%
Q22026-06-3096.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$5.12M

-27.0%

Gross Profit

$4.65M

-25.0%

Gross Margin

90.84%

N/A

Market Cap

$6.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$572.57K

N/A

Employees

11

N/A

Net Income

-$33.14K

+94.4%

EBITDA

-$490.23K

-410.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$6.44M

-11.2%

Total Debt

$1.66M

+19.0%

Accounts Receivable

$1.00M

+37.4%

Inventory

$2.19M

-15.8%

Long Term Debt

$994.80K

-28.6%

Short Term Debt

$667.20K

+11008.9%

Return on Assets

-9.11%

N/A

Return on Invested Capital

-40.80%

N/A

Free Cash Flow

-$460.10K

-167.2%

Operating Cash Flow

-$451.37K

-165.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HITCHealthcare Integrated Technologies, Inc.
$0.30+0.00%
RTGNRetinalGenix Technologies Inc.
$3.99+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$31.76-3.99%
NKENike
$35.15-0.71%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$153.69+3.94%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$34.11-0.87%

Questions About INNPF

What is the current price of InnoCan Pharma?

InnoCan Pharma is trading at $1.40 per share.

What is the 52-week range for InnoCan Pharma?

Over the past 52 weeks, InnoCan Pharma has traded between $1.40 and $14.26.

How much debt does InnoCan Pharma have?

As of the most recent reporting period, InnoCan Pharma reported total debt of $1.66M.

How much cash does InnoCan Pharma have on hand?

InnoCan Pharma reported $6.45M in cash and cash equivalents in its most recent financial results.

What is InnoCan Pharma’s dividend yield?

InnoCan Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services